Pharmacogenomic analysis: Correlating molecular substructure classes with microarray gene expression data

Pharmacogenomics Journal

Volumn 2, Issue 4, 2002, Pages 259-271

  Blower, P E ^a   Yang, C ^a   Fligner, M A ^b   Verducci, J S ^b   Yu, L ^a   Richman, S ^c   Weinstein, J N ^c  

^a Leadscope Inc   (United States)

^b OHIO STATE UNIVERSITY   (United States)

^c NATIONAL CANCER INSTITUTE   (United States)

Author keywords

Molecular class; NCI cell lines; Statistical correlation

Indexed keywords

5 (1 AZIRIDINYL) 3 HYDROXYMETHYL 2 (3 HYDROXY 1 PROPENYL) 1 METHYL 4,7 INDOLEDIONE; ACYLSPHINGOSINE DEACYLASE; ADENOSINE TRIPHOSPHATASE; ANTHRAQUINONE; ANTINEOPLASTIC AGENT; BENZOTHIOPHENE DERIVATIVE; CALDESMON; CYCLOPHILIN; DACTINOMYCIN; DAUNORUBICIN; DOXORUBICIN; GUANINE NUCLEOTIDE BINDING PROTEIN; GYRASE INHIBITOR; IMIDAZOLE DERIVATIVE; INDOLE DERIVATIVE; MATRIX METALLOPROTEINASE 14; MENADIONE; MESSENGER RNA; MITOMYCIN; MITOXANTRONE; NSC 656238; NSC 661223; NSC 682991; PROTEIN RET; QUINONE DERIVATIVE; RAB PROTEIN; THROMBOSPONDIN 1; UBIDECARENONE; UNCLASSIFIED DRUG; UNINDEXED DRUG; ZINC FINGER PROTEIN;

ANALYTIC METHOD; ARTICLE; CELL LINE; CHEMICAL STRUCTURE; CONTROLLED STUDY; CORRELATION ANALYSIS; DATA BASE; DNA MICROARRAY; DRUG STRUCTURE; ELECTRON; GENE EXPRESSION; HUMAN; HUMAN CELL; INHIBITION KINETICS; LEUKEMIA; MELANOMA; ONCOGENE; PHARMACOGENOMICS; PRIORITY JOURNAL; STATISTICAL ANALYSIS; STRUCTURE ACTIVITY RELATION;

ALGORITHMS; ANTINEOPLASTIC AGENTS; CELLS; DATABASES, GENETIC; DRUG DESIGN; GENE EXPRESSION; HUMANS; OLIGONUCLEOTIDE ARRAY SEQUENCE ANALYSIS; PHARMACOGENETICS; QUINONES; TUMOR CELLS, CULTURED;

EID: 0036050211     PISSN: 1470269X     EISSN: None     Source Type: Journal    
DOI: 10.1038/sj.tpj.6500116     Document Type: Article

References (59)

1. Systematic variation in gene expression patterns in human cancer cell lines
2. A gene expression database for the molecular pharmacology of cancer
3. Some practical consideration and applications of the National Cancer Institute in vitro anti-cancer drug discovery screen
4. The NCI anti-cancer drug screen: A smart screen to identify effectors of novel targets
5. Display and analysis of patterns of differential activity of drugs against human tumor cell lines: Development of mean graph and COMPARE algorithm
6. An information intensive approach to the molecular pharmacology of cancer
7. Neural computing in cancer drug development: Predicting mechanism of action
8. Prediction of biochemical mechanism of action from the in vitro antitumor screen of the National Cancer Institute
9. Predictive statistics and artificial intelligence in the US National Cancer Institutes drug discovery program for cancer and AIDS
10. Mining the National Cancer Institute anticancer drug discovery database: Cluster analysis of ellipticine analogs with p53-inverse and central nervous system-selective patterns of activity
11. Mining the NCI anticancer drug discovery databases: Genetic function approximation for the QSAR study of anticancer ellipticine analogues
12. Multidrug-resistant phenotype of disease-oriented panels of human tumor cell lines used for anticancer drug screening
13. Rhodamine efflux patterns predict P-glycoprotein substrates in the National Cancer Institute drug screen
14. Generation of a drug resistance profile by quantitation of MDR-I/P-glycoprotein expression in the cell lines of the NCI anticancer drug screen
15. Molecular targets in the National Cancer Institute drug screen
16. Overlapping phenotypes of multidrug resistance among panels of human cancer-cell lines
17. Enhanced sensitivity to 1-beta-D-arabinofuranosylcytosine and topoisomerase 11 inhibitors in tumor cell lines harboring activated ras oncogenes
18. Characterization of the p53-tumor suppressor pathway in cells of the National Cancer Institute anticancer drug screen and correlations with the growth-inhibitory potency of 123 anticancer agents
19. Identification of compounds with preferential inhibitory activity against low-Nm23-expressing human breast carcinoma and melanoma cell lines
20. Identification of epidermal growth factor receptor and c-erbB2 pathway inhibitors by correlation with gene expression patterns
21. Chemosensitivity prediction by transcriptional profiling
22. LeadScope: Software for exploring large sets of screening data
23. Molecular modeling studies of the DNA-topoisomerase I ternary cleavable complex with camptothecin
24. Binary formal inference-based recursive modeling using multiple atom and physicochemical property class pair and torsion descriptors as decision criteria
25. Quantitative structure-activity relationship of multi-drug resistance reversal agents
26. Diversity analysis of 14 156 molecules tested by the National Cancer Institute for anti-HIV activity using the quantitative structure-activity relational expert system MCASE
27. Fishing Expeditions
28. Pharmacogenomics: Teaching old drugs new tricks
29. Molecular targets in cancer drug discovery: Cell-based profiling
30. Searching for pharmacogenomic markers: The synergy between omic and hypothesis-driven research
31. Rab7: A key to lysosome biogenesis
32. The rab7 GTPase controls the maturation of Salmonella typhimurium-containing vacuoles in HeLa cells
33. Mutant. Rab7 causes the accumulation of cathepsin D and cation-independent mannose 6-phosphate receptor in an early endocytic compartment
34. Molecular cloning and characterization of a human cDNA and gene encoding a novel acid ceramidase-like protein
35. Prediction of the coding sequences of unidentified human genes III. The coding sequences of 40 new genes (KIAA0081-KIAAO120) deduced by analysis of cDNA clones from human cell line KG-1
36. MT1-MMP-deficient mice develop dwarfism, osteopenia, arthritis and connective tissue disease due to inadequate collagen turnover
37. The matrix metalloproteinase-14 (MMP-14) gene is structurally distinct from other MMP genes and is co-expressed with the TIMP-2 gene during mouse embryogenesis
38. Adenine excisional repair function of MYH protein on the adenine:8-hydroxyguanine base pair in double-stranded DNA
39. Identification of human MutY homolog (hMYH) as a repair enzyme for 2-hydroxyadenine in DNA and detection of multiple forms of hMYH located in nuclei and mitochondria
40. Immune complex-induced integrin activation and L-plastin phosphorylation require protein kinase A
41. A role for the actin-bundling protein L-plastin in the regulation of leukocyte integrin function
42. HS1 interacts with Lyn and is critical for erythropoietin-induced differentiation of erythroid cells
43. Molecular features underlying the sequential phosphorylation of HS1 protein and its association with c-Fgr protein-tyrosine kinase
44. RS cyclophilins: Identification of an NK-TR1-related cyclophilin
45. Synthesis and cytotoxicity of Methyl-4, 8-dihydrobenzo[1, 2-b:5, 4-b′]dithiophene-4, 8-dione derivatives
46. Synthesis and cytotoxicity of 2-acetyl-4, 8-dihydrobenzodithiophene-4, 8-dione derivatives
47. Cell line-directed screening assay for inhibitors of thioredoxin reductase signaling as potential anti-cancer drugs
48. α-Anellated carbazoles with anti-tumor activity: Synthesis and cytotoxicity
49. Quinone chemistry and toxicity
50. Molecular mechanisms of quinone cytotoxicity
51. Role of quinones in toxicology
52. Bioreductive activation of a series of indolequinones by human DT-diaphorase: Structure-activity relationships
53. Design of cancer-specific antitumor agents based on aziridinylcyclopent[b]indoloquinones
54. Indolequinone antitumor agents: Relationship between quinone structure and rate of metabolism by recombinant human NQO1
55. Reductase enzyme expression across the National Cancer Institute tumor cell line panel: Correlation with sensitivity to mitomycin C and EO9
56. Inhibitors of DNA-transcribing enyzmes
57. Radiosensitization of cells by aderivative of 2-methyl-1, 4-naphthoquinone
58. Radiation chemistry of quinonoid compounds